Clinical Observation of 10 Stable Nonsegmental Vitiligo Patients in Adults Treated with Upadacitinib

Vitiligo is a chronic immune-related disorder characterized by depigmented skin patches due to melanocyte loss. Traditional treatments often fall short because of significant side effects and limited efficacy. This study evaluated the efficacy and safety of upadacitinib, a selective JAK1 inhibitor, in treating stable nonsegmental vitiligo in adults. We retrospectively analyzed 10 patients treated with upadacitinib at Jingzhou Hospital affiliated with Yangtze University from November 2023 to November 2024. The marked improvement rates were 27.0% at 8 weeks and 52.5% at 16 weeks, while the total efficacy rates were 60.0% and 78.0%, respectively. Efficacy was highest on the face and neck, followed by the trunk, limbs, and extremities. No significant adverse reactions were observed. Our findings suggest that upadacitinib is a safe and effective treatment for stable nonsegmental vitiligo, with efficacy correlated with treatment duration and lesion location. Larger, controlled studies are needed to further explore its therapeutic potential.